文献速递心脑血管急症消化、代谢与肾脏急症

MAGraine:镁剂对比常规药物治疗偏头痛

MAGraine: Magnesium compared to conventional therapy for treatment of migraines.
PubMed 文献 · Am J Emerg Med · 2020-09-14
一句话结论急诊偏头痛成人中,静脉镁剂与丙氯拉嗪、甲氧氯普胺在30分钟疼痛缓解上无显著差异。

该研究为前瞻性随机双盲试验,纳入2019年8月至2020年3月急诊就诊的偏头痛成人,排除孕妇及肾功能不全者。患者随机接受静脉镁剂、丙氯拉嗪或甲氧氯普胺。主要终点为输注开始后30分钟数字评定量表(NRS)疼痛较基线的变化。60分钟、120分钟NRS、急诊停留时间、补救镇痛需求及不良事件均无显著差异。

要点

  • 三组30分钟NRS中位下降均为3分,镁剂与丙氯拉嗪、甲氧氯普胺在主要终点无显著差异。
  • 60分钟NRS中位下降(IQR):镁剂-4(2-6),甲氧氯普胺-3(2-5),丙氯拉嗪-4.5(2-7),p=0.27。
  • 急诊停留时间、补救镇痛需求及不良事件在三组间无统计学显著差异。
  • 报告的不良事件包括头晕、焦虑和静坐不能。
  • 研究排除孕妇及肾功能不全患者,适用人群为急诊成人偏头痛患者。

适用人群与场景

  • 急诊就诊的成人偏头痛患者,年龄中位数36岁,多数为白人女性,常见合并症为高血压和偏头痛,约三分之一报告先兆。
  • 排除孕妇及肾功能不全患者。

诊断标准与关键阈值

  • 偏头痛诊断由急诊医师作出。
  • 疼痛评估采用数字评定量表(NRS)。

处置流程与药物剂量

  • 原文未提及具体药物剂量、给药途径、频次或疗程。

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 干预:静脉镁剂 vs 丙氯拉嗪 vs 甲氧氯普胺;主要终点为30分钟NRS较基线变化,三组中位下降均为3分,无显著差异。
  • 关键次要终点:60分钟NRS中位下降(IQR)镁剂-4(2-6)、甲氧氯普胺-3(2-5)、丙氯拉嗪-4.5(2-7),p=0.27;急诊停留时间、补救镇痛及不良事件无显著差异。
  • 不良事件:头晕、焦虑、静坐不能。

证据类型、等级与局限

  • 证据类型:前瞻性随机双盲试验。
  • 原文未述证据等级或推荐强度。
  • 原文未述局限性。

对床旁实践的改变

  • 对于急诊成人偏头痛患者(排除孕妇及肾功能不全),静脉镁剂可作为与丙氯拉嗪、甲氧氯普胺等效的镇痛选择之一,30分钟疼痛缓解无显著差异。
  • 选择药物时需考虑不良事件谱:镁剂组报告头晕、焦虑,甲氧氯普胺和丙氯拉嗪组报告静坐不能。
  • 原文未提及具体剂量,临床使用时需参照当地常规方案。

指南或共识出处

  • 原文未提及

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

Due to the healthcare burden associated with migraines, prompt and effective treatment is vital to improve patient outcomes and ED workflow. This was a prospective, randomized, double-blind trial. Adults who presented to the ED with a diagnosis of migraine from August of 2019 to March of 2020 were included. Pregnant patients, or with renal impairment were excluded. Patients were randomized to receive intravenous magnesium, prochlorperazine, or metoclopramide. The primary outcome was change in pain from baseline on a numeric rating scale (NRS) evaluated at 30 min after initiation of infusion of study drug. Secondary outcomes included NRS at 60 and 120 min, ED length of stay, necessity for rescue analgesia, and adverse effects. A total of 157 patients were analyzed in this study. Sixty-one patients received magnesium, 52 received prochlorperazine, and 44 received metoclopramide. Most patients were white females, and the median age was 36 years. Hypertension and migraines were the most common comorbidities, with a third of the patients reporting an aura. There was a median decrease in NRS at 30 min of three points across all three treatment arms. The median decrease in NRS (IQR) at 60 min was -4 (2-6) in the magnesium group, -3 (2-5) in the metoclopramide group, and -4.5 (2-7) in the prochlorperazine group (p = 0.27). There were no statistically significant differences in ED length of stay, rescue analgesia, or adverse effects. Reported adverse effects were dizziness, anxiety, and akathisia. No significant difference was observed in NRS at 30 min between magnesium, metoclopramide and prochlorperazine.

来源:Am J Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Kandil M, Jaber S, Desai D, et al. MAGraine: Magnesium compared to conventional therapy for treatment of migraines. Am J Emerg Med. 2020. PMID: 33041146. doi:10.1016/j.ajem.2020.09.033

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。